Vista Pharmaceuticals (BOM:524711) EV-to-EBIT : -18.46 (As of Jun. 08, 2024)

View and export this data going back to 1994. Start your Free Trial

What is Vista Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vista Pharmaceuticals's Enterprise Value is ₹730.6 Mil. Vista Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-39.6 Mil. Therefore, Vista Pharmaceuticals's EV-to-EBIT for today is -18.46.

The historical rank and industry rank for Vista Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

BOM:524711' s EV-to-EBIT Range Over the Past 10 Years
Min: -244.16 Med: -8.35 Max: 67.69
Current: -18.46

During the past 13 years, the highest EV-to-EBIT of Vista Pharmaceuticals was 67.69. The lowest was -244.16. And the median was -8.35.

BOM:524711's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 16.7 vs BOM:524711: -18.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Vista Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ₹578.6 Mil. Vista Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-39.6 Mil. Vista Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -6.84%.

Vista Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Vista Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vista Pharmaceuticals EV-to-EBIT Chart

Vista Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EV-to-EBIT

Get a 7-Day Free Trial

-12.21

-19.37

-27.01

-8.84

-14.62

Vista Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-8.84	-7.97	-13.84	-8.99	-14.62

Competitive Comparison of Vista Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Vista Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vista Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vista Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vista Pharmaceuticals's EV-to-EBIT falls into.

Vista Pharmaceuticals EV-to-EBIT Calculation

Vista Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	730.589	/	-39.576
	=	-18.46

Vista Pharmaceuticals's current Enterprise Value is ₹730.6 Mil.
Vista Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-39.6 Mil.

Vista Pharmaceuticals (BOM:524711) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vista Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-39.576	/	578.638812
	=	-6.84 %

Vista Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ₹578.6 Mil.
Vista Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-39.6 Mil.

Vista Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Vista Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vista Pharmaceuticals (BOM:524711) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vista Pharmaceuticals Ltd (BOM:524711) » Definitions » EV-to-EBIT

Traded in Other Exchanges

N/A

Address

Plot No. 104, Kakateeya Hills, Ravindra Co OP Society Guttala Begumpet, Hyderabad, TG, IND, 500033

Website

http://www.vistapharmaceuticals.com

Vista Pharmaceuticals Ltd is an Indian based company engaged in single operating segments that is the manufacturing of Pharmaceutical products. The company offers over the counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, Indomethacin are the drugs offered by the company in a capsule dosage form. The business is carried out in India.

Vista Pharmaceuticals (BOM:524711) Headlines

No Headlines